Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: A roadmap for preclinical development

Frontiers in Neuroscience

Volumn , Issue 7 JUN, 2013, Pages

  Acheson, Dean T ^a,b   Twamley, Elizabeth W ^a,c   Young, Jared W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b San Diego Veterans Healthcare Administration   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Augmentation; Cognitive remediation; DRD1; NAChR; Schizophrenia

Indexed keywords

ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST; DOPAMINE 1 RECEPTOR STIMULATING AGENT; NICOTINIC AGENT; UNCLASSIFIED DRUG;

COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; EFFECT SIZE; HUMAN; LEARNING; NERVE CELL PLASTICITY; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSITIVE FEEDBACK; POSITIVE SYNDROME; POSTTRAUMATIC STRESS DISORDER; PSYCHOSOCIAL CARE; REVIEW; REWARD; SCHIZOPHRENIA; SOCIAL ADAPTATION; SOCIAL PHOBIA;

EID: 84899743515     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2013.00103     Document Type: Review

References (156)

1. Acheson, D. T., Feifel, D., de Wilde, S., Mckinney, R., Lohr, J., and Risbrough, V. B. (2013). The effect of intranasal oxytocin treatment on conditioned fear extinction in a healthy human sample. Psychopharmacology (Berl.). doi: 10.1007/s00213-013-3099-4. [Epub ahead of print].
2. Amodeo, D. A., Jones, J. H., Sweeney, J. A., and Ragozzino, M. E. (2012). Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors. Behav. Brain Res. 227, 64-72. doi: 10.1016/j.bbr.2011.10.032
3. Andero, R., and Ressler, K. J. (2012). Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav. 11, 503-512. doi: 10.1111/j.1601-183X.2012.00801.x
4. Arendash, G. W., Sanberg, P. R., and Sengstock, G. J. (1995a). Nicotine enhances the learning and memory of aged rats. Pharmacol. Biochem. Behav. 52, 517-523. doi: 10.1016/0091-3057(95)00119-H
5. Arendash, G. W., Sengstock, G. J., Sanberg, P. R., and Kem, W. R. (1995b). Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674, 252-259. doi: 10.1016/0006-8993(94)01449-R
6. Bari, A., Theobald, D. E., Caprioli, D., Mar, A. C., Aidoo-Micah, A., Dalley, J. W., et al. (2010). Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. Neuropsychopharmacology 35, 1290-1301. doi: 10.1038/npp.2009.233
7. Barr, R. S., Culhane, M. A., Jubelt, L. E., Mufti, R. S., Dyer, M. A., Weiss, A. P., et al. (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33, 480-490. doi: 10.1038/sj.npp.1301423
8. Bencherif, M., Stachowiak, M. K., Kucinski, A. J., and Lippiello, P. M. (2012). Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Med. Hypotheses 78, 594-600. doi: 10.1016/j.mehy.2012.01.035
9. Bentz, D., Michael, T., De Quervain, D. J., and Wilhelm, F. H. (2010). Enhancing exposure therapy for anxiety disorders with glucocorticoids: from basic mechanisms of emotional learning to clinical applications. J. Anxiety Disord. 24, 223-230. doi: 10.1016/j.janxdis.2009.10.011
10. Bigos, K. L., Mattay, V. S., Callicott, J. H., Straub, R. E., Vakkalanka, R., Kolachana, B., et al. (2010). Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch. Gen. Psychiatry 67, 939-945. doi: 10.1001/archgenpsychiatry.2010.96
11. Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., et al. (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159, 1018-1028. doi: 10.1176/appi.ajp.159.6.1018
12. Blanchet, P. J., Fang, J., Gillespie, M., Sabounjian, L., Locke, K. W., Gammans, R., et al. (1998). Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin. Neuropharmacol. 21, 339-343.
13. Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., et al. (2007). Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 165, 82-89. doi: 10.1176/appi.ajp.2007.07050724
14. Buchanan, R. W., Davis, M., Goff, D., Green, M. F., Keefe, R. S., Leon, A. C., et al. (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31, 5-19. doi: 10.1093/schbul/sbi020
15. Carter, C. S. (2005). Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. Schizophr. Bull. 31, 810-815. doi: 10.1093/schbul/sbi046
16. Carter, C. S., and Barch, D. M. (2007). Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr. Bull. 33, 1131-1137. doi: 10.1093/schbul/sbm081
17. Chamberlain, S. R., Muller, U., Blackwell, A. D., Clark, L., Robbins, T. W., and Sahakian, B. J. (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311, 861-863. doi: 10.1126/science.1121218
18. Chou, H., Twamley, E., and Swerdlow, N. R. (2012). Towards medication-enhancement of cognitive interventions in schizophrenia. Handb. Exp. Pharmacol. 213, 81-111. doi: 10.1007/978-3-642-25758-2_4
19. Davis, M. (2002). Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur. J. Neurosci. 16, 395-398. doi: 10.1046/j.1460-9568.2002.02138.x
20. Daw, N. D., Gershman, S. J., Seymour, B., Dayan, P., and Dolan, R. J. (2011). Model-based influences on humans' choices and striatal prediction errors. Neuron 69, 1204-1215. doi: 10.1016/j.neuron.2011.02.027
21. Deacon, B. J., and Abramowitz, J. S. (2004). Cognitive and behavioral treatments for anxiety disorders: a review of meta-analytic findings. J. Clin. Psychol. 60, 429-441. doi: 10.1002/jclp.10255
22. De Kleine, R. A., Hendriks, G. J., Kusters, W. J., Broekman, T. G., and Van Minnen, A. (2012). A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol. Psychiatry 71, 962-968. doi: 10.1016/j.biopsych.2012.02.033
23. Devito, L. M., Lykken, C., Kanter, B. R., and Eichenbaum, H. (2010). Prefrontal cortex: role in acquisition of overlapping associations and transitive inference. Learn. Mem. 17, 161-167. doi: 10.1101/lm.1685710
24. Dickinson, D., Tenhula, W., Morris, S., Brown, C., Peer, J., Spencer, K., et al. (2010). A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am. J. Psychiatry 167, 170-180. doi: 10.1176/appi.ajp.2009.09020264
25. Dolan, S. L., Sacco, K. A., Termine, A., Seyal, A. A., Dudas, M. M., Vessicchio, J. C., et al. (2004). Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr. Res. 70, 263-275. doi: 10.1016/j.schres.2004.01.006
26. D'Souza, M. S., and Markou, A. (2012). Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 62, 1564-1573. doi: 10.1016/j.neuropharm.2011.01.044
27. Dudchenko, P. A., Talpos, J., Young, J., and Baxter, M. G. (2012). Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2012.03.003. [Epub ahead of print].
28. Dusek, J. A., and Eichenbaum, H. (1997). The hippocampus and memory for orderly stimulus relations. Proc. Natl. Acad. Sci. U.S.A. 94, 7109-7114. doi: 10.1073/pnas.94.13.7109
29. Dwoskin, L. P., Pivavarchyk, M., Joyce, B. M., Neugebauer, N. M., Zheng, G., Zhang, Z., et al. (2009). Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr. Symp. Motiv. 55, 31-63. doi: 10.1007/978-0-387-78748-0_4
30. Dziewczapolski, G., Glogowski, C. M., Masliah, E., and Heinemann, S. F. (2009). Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J. Neurosci. 29, 8805-8815. doi: 10.1523/JNEUROSCI.6159-08.2009
31. Enomoto, K., Matsumoto, N., Nakai, S., Satoh, T., Sato, T. K., Ueda, Y., et al. (2011). Dopamine neurons learn to encode the long-term value of multiple future rewards. Proc. Natl. Acad. Sci. U.S.A. 108, 15462-15467. doi: 10.1073/pnas.1014457108
32. Fisher, M., Holland, C., Subramaniam, K., and Vinogradov, S. (2010). Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr. Bull. 36, 869-879. doi: 10.1093/schbul/sbn170
33. Floresco, S. B., Geyer, M. A., Gold, L. H., and Grace, A. A. (2005). Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr. Bull. 31, 888-894. doi: 10.1093/schbul/sbi041
34. Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., et al. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U.S.A. 94, 587-592. doi: 10.1073/pnas.94.2.587
35. Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., et al. (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165, 1040-1047. doi: 10.1176/appi.ajp.2008.07071135
36. Furukawa, T. A., Watanabe, N., and Churchill, R. (2006). Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br. J. Psychiatry 188, 305-312. doi: 10.1192/bjp.188.4.305
37. George, M. S., Molnar, C. E., Grenesko, E. L., Anderson, B., Mu, Q., Johnson, K., et al. (2007). A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr. Res. 93, 42-50. doi: 10.1016/j.schres.2007.03.011
38. Gerfen, C. R., and Engber, T. M. (1992). Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach. Neurol. Clin. 10, 435-449.
39. Geyer, M. A. (2010). New opportunities in the treatment of cognitive impairments associated with schizophrenia. Curr. Dir. Psychol. Sci. 19, 264-269. doi: 10.1177/0963721410378359
40. Glimcher, P. W. (2011). Understanding dopamine and reinforcement learning: the dopamine reward prediction error hypothesis. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 3), 15647-15654. doi: 10.1073/pnas.1014269108
41. Gradin, V. B., Kumar, P., Waiter, G., Ahearn, T., Stickle, C., Milders, M., et al. (2011). Expected value and prediction error abnormalities in depression and schizophrenia. Brain 134, 1751-1764. doi: 10.1093/brain/awr059
42. Granado, N., Ortiz, O., Suarez, L. M., Martin, E. D., Cena, V., Solis, J. M., et al. (2008). D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb. Cortex 18, 1-12. doi: 10.1093/cercor/bhm026
43. Grottick, A. J., Haman, M., Wyler, R., and Higgins, G. A. (2003). Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 28, 880-887. doi: 10.1038/sj.npp.1300102
44. Gutierrez-Recacha, P., Chisholm, D., Haro, J. M., Salvador-Carulla, L., and Ayuso-Mateos, J. L. (2006). Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. Acta Psychiatr. Scand. Suppl. 432, 29-38. doi: 10.1111/j.1600-0447.2006.00917.x
45. Hagan, J. J., and Jones, D. N. (2005). Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31, 830-853. doi: 10.1093/schbul/sbi058
46. Hahn, B., Gold, J. M., and Buchanan, R. W. (2013). The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Neuropharmacology 64, 185-190. doi: 10.1016/j.neuropharm.2012.05.050
47. Hahn, B., Shoaib, M., and Stolerman, I. P. (2011). Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement. Psychopharmacology (Berl) 217, 75-82. doi: 10.1007/s00213-011-2258-8
48. Harrison, P. J., and Law, A. J. (2006). Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 60, 132-140. doi: 10.1016/j.biopsych.2005.11.002
49. Harvey, P. D., and Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158, 176-184. doi: 10.1176/appi.ajp.158.2.176
50. Hasan, A., Nitsche, M. A., Rein, B., Schneider-Axmann, T., Guse, B., Gruber, O., et al. (2011). Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav. Brain Res. 224, 15-22. doi: 10.1016/j.bbr.2011.05.017
51. Heinrichs, R. W. (2007). Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 631-632. doi: 10.1001/archpsyc.64.6.631
52. Javitt, D. C., Buchanan, R. W., Keefe, R. S., Kern, R., McMahon, R. P., Green, M. F., et al. (2012). Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 136, 25-31. doi: 10.1016/j.schres.2011.11.001
53. Joshua, M., Adler, A., Mitelman, R., Vaadia, E., and Bergman, H. (2008). Midbrain dopaminergic neurons and striatal cholinergic interneurons encode the difference between reward and aversive events at different epochs of probabilistic classical conditioning trials. J. Neurosci. 28, 11673-11684. doi: 10.1523/JNEUROSCI.3839-08.2008
54. Juckel, G., Schlagenhauf, F., Koslowski, M., Wustenberg, T., Villringer, A., Knutson, B., et al. (2006). Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29, 409-416. doi: 10.1016/j.neuroimage.2005.07.051
55. Keefe, R. S., Bilder, R. M., Davis, S. M., Harvey, P. D., Palmer, B. W., Gold, J. M., et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633-647. doi: 10.1001/archpsyc.64.6.633
56. Keefe, R. S., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., et al. (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr. Bull. 39, 417-435. doi: 10.1093/schbul/sbr153
57. Keefe, R. S., Vinogradov, S., Medalia, A., Silverstein, S. M., Bell, M. D., Dickinson, D., et al. (2011). Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr. Bull. 37, 1057-1065. doi: 10.1093/schbul/sbq010
58. Keller, J. J., Keller, A. B., Bowers, B. J., and Wehner, J. M. (2005). Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behav. Brain Res. 162, 143-152. doi: 10.1016/j.bbr.2005.03.004
59. Kern, R. S., Glynn, S. M., Horan, W. P., and Marder, S. R. (2009). Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr. Bull. 35, 347-361. doi: 10.1093/schbul/sbn177
60. Kleinman, J. E., Law, A. J., Lipska, B. K., Hyde, T. M., Ellis, J. K., Harrison, P. J., et al. (2011). Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains. Biol. Psychiatry 69, 140-145. doi: 10.1016/j.biopsych.2010.10.032
61. Kroker, K. S., Rast, G., and Rosenbrock, H. (2011). Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP. Eur. J. Pharmacol. 671, 26-32. doi: 10.1016/j.ejphar.2011.09.167
62. Krystal, J. H. (2007). Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy. Biol. Psychiatry 62, 833-834. doi: 10.1016/j.biopsych.2007.08.017
63. Kumari, V., and Postma, P. (2005). Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 29, 1021-1034. doi: 10.1016/j.neubiorev.2005.02.006
64. Kuriyama, K., Honma, M., Soshi, T., Fujii, T., and Kim, Y. (2011). Effect of D-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial. Psychopharmacology (Berl.) 218, 589-597. doi: 10.1007/s00213-011-2353-x
65. Kurtz, M. M., and Mueser, K. T. (2008). A meta-analysis of controlled research on social skills training for schizophrenia. J. Consult. Clin. Psychol. 76, 491-504. doi: 10.1037/0022-006X.76.3.491
66. Kurtz, M. M., and Richardson, C. L. (2012). Social cognitive training for schizophrenia: a meta-analytic investigation of controlled research. Schizophr. Bull. 38, 1092-1104. doi: 10.1093/schbul/sbr036
67. Kurtz, M. M., Seltzer, J. C., Shagan, D. S., Thime, W. R., and Wexler, B. E. (2007). Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient? Schizophr. Res. 89, 251-260. doi: 10.1016/j.schres.2006.09.001
68. Lagostena, L., Trocme-Thibierge, C., Morain, P., and Cherubini, E. (2008). The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 54, 676-685. doi: 10.1016/j.neuropharm.2007.11.016
69. Law, A. J., Lipska, B. K., Weickert, C. S., Hyde, T. M., Straub, R. E., Hashimoto, R., et al. (2006). Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc. Natl. Acad. Sci. U.S.A. 103, 6747-6752. doi: 10.1073/pnas.0602002103
70. Levin, E. D. (2002). Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53, 633-640. doi: 10.1002/neu.10151
71. Levin, E. D., Bradley, A., Addy, N., and Sigurani, N. (2002). Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109, 757-765. doi: 10.1016/S0306-4522(01)00538-3
72. Levin, E. D., Conners, C. K., Silva, D., Hinton, S. C., Meck, W. H., March, J., et al. (1998). Transdermal nicotine effects on attention. Psychopharmacology (Berl.) 140, 135-141. doi: 10.1007/s002130050750
73. Levin, E. D., Lee, C., Rose, J. E., Reyes, A., Ellison, G., Jarvik, M., et al. (1990). Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav. Neural Biol. 53, 269-276. doi: 10.1016/0163-1047(90)90509-5
74. Levin, E. D., Petro, A., Rezvani, A. H., Pollard, N., Christopher, N. C., Strauss, M., et al. (2009). Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav. Brain Res. 196, 207-213. doi: 10.1016/j.bbr.2008.08.048
75. Levin, E. D., and Rezvani, A. H. (2006). Nicotinic-antipsychotic drug interactions and cognitive function. EXS 98, 185-205. doi: 10.1007/978-3-7643-7772-4_10
76. Levitt, J. J., Bobrow, L., Lucia, D., and Srinivasan, P. (2010). A selective review of volumetric and morphometric imaging in schizophrenia. Curr. Top. Behav. Neurosci. 4, 243-281. doi: 10.1007/7854_2010_53
77. Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., et al. (2013). A Randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38, 968-975. doi: 10.1038/npp.2012.259
78. Liu, Y., Young, K. A., Curtis, J. T., Aragona, B. J., and Wang, Z. (2011). Social bonding decreases the rewarding properties of amphetamine through a dopamine D1 receptor-mediated mechanism. J. Neurosci. 31, 7960-7966. doi: 10.1523/JNEUROSCI.1006-11.2011
79. Luck, S. J., Ford, J. M., Sarter, M., and Lustig, C. (2011). CNTRICS final biomarker selection: control of attention. Schizophr. Bull. 38, 53-61. doi: 10.1093/schbul/sbr065
80. Lustig, C., Kozak, R., Sarter, M., Young, J. W., and Robbins, T. W. (2012). CNTRICS final animal model task selection: control of attention. Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2012.05.009. [Epub ahead of print].
81. Marder, S. R. (2006). Drug initiatives to improve cognitive function. J. Clin. Psychiatry 67(Suppl. 9), 31-35. discussion: 36-42. doi: 10.4088/JCP.0706e03
82. Marder, S. R., and Fenton, W. (2004). Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res. 72, 5-9. doi: 10.1016/j.schres.2004.09.010
83. Martin, L. F., Kem, W. R., and Freedman, R. (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl.) 174, 54-64. doi: 10.1007/s00213-003-1750-1
84. Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., et al. (2003). Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol. Psychiatry 54, 1222-1233. doi: 10.1016/S0006-3223(03)00348-2
85. Mathew, S. V., Law, A. J., Lipska, B. K., Davila-Garcia, M. I., Zamora, E. D., Mitkus, S. N., et al. (2007). Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum. Mol. Genet. 16, 2921-2932. doi: 10.1093/hmg/ddm253
86. Matsumoto, M., and Hikosaka, O. (2009). Representation of negative motivational value in the primate lateral habenula. Nat. Neurosci. 12, 77-84. doi: 10.1038/nn.2233
87. Matthies, H., Becker, A., Schroeder, H., Kraus, J., Hollt, V., and Krug, M. (1997). Dopamine D1-deficient mutant mice do not express the late phase of hippocampal long-term potentiation. Neuroreport 8, 3533-3535. doi: 10.1097/00001756-199711100-00023
88. McCorvy, J. D., Watts, V. J., and Nichols, D. E. (2012). Comparison of the D(1) dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology (Berl.) 222, 81-87. doi: 10.1007/s00213-011-2625-5
89. McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J., and Mueser, K. T. (2007). A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 164, 1791-1802. doi: 10.1176/appi.ajp.2007.07060906
90. McOmish, C. E., and Hannan, A. J. (2007). Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders. Expert Opin. Ther. Targets 11, 899-913. doi: 10.1517/14728222.11.7.899
91. Mintz, J., and Kopelowicz, A. (2007). CUtLASS confirms CATIE. Arch. Gen. Psychiatry 64, 978; author reply: 979-980. doi: 10.1001/archpsyc.64.8.978-a
92. Minzenberg, M. J., and Carter, C. S. (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33, 1477-1502. doi: 10.1038/sj.npp.1301534
93. Montague, P. R., McClure, S. M., Baldwin, P. R., Phillips, P. E., Budygin, E. A., Stuber, G. D., et al. (2004). Dynamic gain control of dopamine delivery in freely moving animals. J. Neurosci. 24, 1754-1759. doi: 10.1523/JNEUROSCI.4279-03.2004
94. Morris, G., Schmidt, R., and Bergman, H. (2010). Striatal action-learning based on dopamine concentration. Exp. Brain Res. 200, 307-317. doi: 10.1007/s00221-009-2060-6
95. Mu, Q., Johnson, K., Morgan, P. S., Grenesko, E. L., Molnar, C. E., Anderson, B., et al. (2007). A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res. 94, 332-341. doi: 10.1016/j.schres.2007.03.033
96. Myers, C. S., Taylor, R. C., Moolchan, E. T., and Heishman, S. J. (2008). Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology 33, 588-598. doi: 10.1038/sj.npp.1301425
97. Newhouse, P., Singh, A., and Potter, A. (2004). Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr. Top. Med. Chem. 4, 267-282. doi: 10.2174/1568026043451401
98. Newhouse, P. A., Potter, A., Corwin, J., and Lenox, R. (1992). Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl.) 108, 480-484. doi: 10.1007/BF02247425
99. Nicoll, R. A., and Roche, K. W. (2013). Long-term potentiation: peeling the onion. Neuropharmacology. doi: 10.1016/j.neuropharm.2013.02.010. [Epub ahead of print].
100. Norberg, M. M., Krystal, J. H., and Tolin, D. F. (2008). A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 63, 1118-1126. doi: 10.1016/j.biopsych.2008.01.012
101. Nutt, D., and Goodwin, G. (2011). ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur. Neuropsychopharmacol. 21, 495-499. doi: 10.1016/j.euroneuro.2011.05.004
102. Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., et al. (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63, 630-638. doi: 10.1001/archpsyc.63.6.630
103. Ortiz, O., Delgado-Garcia, J. M., Espadas, I., Bahi, A., Trullas, R., Dreyer, J. L., et al. (2010). Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J. Neurosci. 30, 12288-12300. doi: 10.1523/JNEUROSCI.2655-10.2010
104. Otto, M. W., McHugh, R. K., and Kantak, K. M. (2010a). Combined pharmacotherapy and cognitive-behavioral therapy for axiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes. Clin. Psychol. Sci. Prac. 17, 91-103. doi: 10.1111/j.1468-2850.2010.01198.x
105. Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., et al. (2010b). Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol. Psychiatry 67, 365-370. doi: 10.1016/j.biopsych.2009.07.036
106. Patterson, T. L., and Leeuwenkamp, O. R. (2008). Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr. Res. 100, 108-119. doi: 10.1016/j.schres.2007.12.468
107. Paylor, R., Nguyen, M., Crawley, J. N., Patrick, J., Beaudet, A., and Orr-Urtreger, A. (1998). Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn. Mem. 5, 302-316. doi: 10.1101/lm.5.4.302
108. Pfammatter, M., Junghan, U. M., and Brenner, H. D. (2006). Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophr. Bull. 32(Suppl. 1), S64-S80. doi: 10.1093/schbul/sbl030
109. Poltavski, D. V., and Petros, T. (2006). Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. Physiol. Behav. 87, 614-624. doi: 10.1016/j.physbeh.2005.12.011
110. Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., and Newhouse, P. A. (1999). Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl.) 142, 334-342. doi: 10.1007/s002130050897
111. Przybyla, J. A., Cueva, J. P., Chemel, B. R., Hsu, K. J., Riese, D. J. 2nd., McCorvy, J. D., et al. (2009). Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. Eur. Neuropsychopharmacol. 19, 138-146. doi: 10.1016/j.euroneuro.2008.10.002
112. Qu, W. M., Huang, Z. L., Xu, X. H., Matsumoto, N., and Urade, Y. (2008). Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J. Neurosci. 28, 8462-8469. doi: 10.1523/JNEUROSCI.1819-08.2008
113. Ragland, J. D., Cools, R., Frank, M., Pizzagalli, D. A., Preston, A., Ranganath, C., et al. (2009). CNTRICS final task selection: long-term memory. Schizophr. Bull. 35, 197-212. doi: 10.1093/schbul/sbn134
114. Rezvani, A. H., Kholdebarin, E., Brucato, F. H., Callahan, P. M., Lowe, D. A., and Levin, E. D. (2009). Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 269-275. doi: 10.1016/j.pnpbp.2008.11.018
115. Roder, V., Mueller, D. R., Mueser, K. T., and Brenner, H. D. (2006). Integrated psychological therapy (IPT) for schizophrenia: is it effective? Schizophr. Bull. 32(Suppl. 1), S81-S93. doi: 10.1093/schbul/sbl021
116. Rushforth, S. L., Allison, C., Wonnacott, S., and Shoaib, M. (2010). Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task. Neurosci. Lett. 471, 114-118. doi: 10.1016/j.neulet.2010.01.022
117. Schultz, W. (2002). Getting formal with dopamine and reward. Neuron 36, 241-263. doi: 10.1016/S0896-6273(02)00967-4
118. Scoriels, L., Jones, P. B., and Sahakian, B. J. (2013). Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 64, 168-184. doi: 10.1016/j.neuropharm.2012.07.011
119. Sheinin, A., Shavit, S., and Benveniste, M. (2001). Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41, 151-158. doi: 10.1016/S0028-3908(01)00073-9
120. Silverstein, S. M., Spaulding, W. D., Menditto, A. A., Savitz, A., Liberman, R. P., Berten, S., et al. (2009). Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. Schizophr. Bull. 35, 222-232. doi: 10.1093/schbul/sbm150
121. Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., Gudfinnsson, E., et al. (2003). Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am. J. Hum. Genet. 72, 83-87. doi: 10.1086/345442
122. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892. doi: 10.1086/342734
123. Strauss, G. P., Frank, M. J., Waltz, J. A., Kasanova, Z., Herbener, E. S., and Gold, J. M. (2011). Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol. Psychiatry 69, 424-431. doi: 10.1016/j.biopsych.2010.10.015
124. Surmeier, D. J., Plotkin, J., and Shen, W. (2009). Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr. Opin. Neurobiol. 19, 621-628. doi: 10.1016/j.conb.2009.10.003
125. Swerdlow, N. R. (2011). Are we studying and treating schizophrenia correctly? Schizophr. Res. 130, 1-10. doi: 10.1016/j.schres.2011.05.004
126. Tamminga, C. A. (2006). The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 67(Suppl. 9), 9-13. discussion: 36-42. doi: 10.4088/JCP.0906e11
127. Taylor, G. T., Bassi, C. J., and Weiss, J. (2005). Limits of learning enhancements with nicotine in old male rats. Acta Neurobiol. Exp. (Wars.) 65, 125-136.
128. Thomsen, M. S., Hay-Schmidt, A., Hansen, H. H., and Mikkelsen, J. D. (2010). Distinct neural pathways mediate alpha7 nicotinic acetylcholine receptor-dependent activation of the forebrain. Cereb. Cortex 20, 2092-2102. doi: 10.1093/cercor/bhp283
129. Titone, D., Ditman, T., Holzman, P. S., Eichenbaum, H., and Levy, D. L. (2004). Transitive inference in schizophrenia: impairments in relational memory organization. Schizophr. Res. 68, 235-247. doi: 10.1016/S0920-9964(03)00152-X
130. Tobler, P. N., Fiorillo, C. D., and Schultz, W. (2005). Adaptive coding of reward value by dopamine neurons. Science 307, 1642-1645. doi: 10.1126/science.1105370
131. Twamley, E. W., Jeste, D. V., and Bellack, A. S. (2003). A review of cognitive training in schizophrenia. Schizophr. Bull. 29, 359-382. doi: 10.1093/oxfordjournals.schbul.a007011
132. Twamley, E. W., Vella, L., Burton, C. Z., Heaton, R. K., and Jeste, D. V. (2012). Compensatory Cognitive Training for psychosis: effects in a randomized controlled trial. J. Clin. Psychiatry 73, 1212-1219. doi: 10.4088/JCP.12m07686
133. Vinogradov, S., Fisher, M., Holland, C., Shelly, W., Wolkowitz, O., and Mellon, S. H. (2009a). Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol. Psychiatry 66, 549-553. doi: 10.1016/j.biopsych.2009.02.017
134. Vinogradov, S., Fisher, M., Warm, H., Holland, C., Kirshner, M. A., and Pollock, B. G. (2009b). The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 166, 1055-1062. doi: 10.1176/appi.ajp.2009.09010017
135. Waltz, J. A., Frank, M. J., Robinson, B. M., and Gold, J. M. (2007). Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol. Psychiatry 62, 756-764. doi: 10.1016/j.biopsych.2006.09.042
136. Waltz, J. A., Frank, M. J., Wiecki, T. V., and Gold, J. M. (2011). Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology 25, 86-97. doi: 10.1037/a0020882
137. Waltz, J. A., Knowlton, B. J., Hoyoak, K. J., Boone, K. B., Mishkin, F. S., De Menedezes Santos, M., et al. (1999). A system for relational reasoining in human prefrontal cortex. Psychol. Sci. 10, 119-125. doi: 10.1111/1467-9280.00118
138. Weiler, J. A., Bellebaum, C., Brune, M., Juckel, G., and Daum, I. (2009). Impairment of probabilistic reward-based learning in schizophrenia. Neuropsychology 23, 571-580. doi: 10.1037/a0016166
139. Weiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl.) 177, 207-216. doi: 10.1007/s00213-004-1940-5
140. Weiss, E. M., Bilder, R. M., and Fleischhacker, W. W. (2002). The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl.) 162, 11-17. doi: 10.1007/s00213-002-1053-y
141. Wolf, M. E., Sun, X., Mangiavacchi, S., and Chao, S. Z. (2004). Psychomotor stimulants and neuronal plasticity. Neuropharmacology 47(Suppl. 1), 61-79. doi: 10.1016/j.neuropharm.2004.07.006
142. Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., and Czobor, P. (2011). A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 168, 472-485. doi: 10.1176/appi.ajp.2010.10060855
143. Wykes, T., Steel, C., Everitt, B., and Tarrier, N. (2008). Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 34, 523-537. doi: 10.1093/schbul/sbm114
144. Young, J. W. (2009). Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness. J. Neurosci. 29, 2663-2665. doi: 10.1523/JNEUROSCI.5843-08.2009
145. Young, J. W., Amitai, N., and Geyer, M. A. (2012a). "Behavioral animal models to assess pro-cognitive treatments for schizophrenia," in Hanbook of Experimental Pharmacology, eds M. A. Geyer and G. Gross (Heidelberg: Springer), 39-79.
146. Young, J. W., Jentsch, J. D., Bussey, T. J., Wallace, T. L., and Hutcheson, D. M. (2012b). Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2012.10.002. [Epub ahead of print].
147. Young, J. W., Powell, S. B., and Geyer, M. A. (2012c). Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology 62, 1381-1390. doi: 10.1016/j.neuropharm.2011.06.013
148. Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., et al. (2007a). Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur. Neuropsychopharmacol. 17, 145-155. doi: 10.1016/j.euroneuro.2006.03.008
149. Young, J. W., Kerr, L. E., Kelly, J. S., Marston, H. M., Spratt, C., Finlayson, K., et al. (2007b). The odour span task: a novel paradigm for assessing working memory in mice. Neuropharmacology 52, 634-645. doi: 10.1016/j.neuropharm.2006.09.006
150. Young, J. W., Finlayson, K., Spratt, C., Marston, H. M., Crawford, N., Kelly, J. S., et al. (2004). Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29, 891-900. doi: 10.1038/sj.npp.1300393
151. Young, J. W., and Geyer, M. A. (2010). Action of modafinil-increased motivation via the dopamine transporter inhibition and D1 receptors? Biol. Psychiatry 67, 784-787. doi: 10.1016/j.biopsych.2009.12.015
152. Young, J. W., Meves, J. M., and Geyer, M. A. (2013). Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav. Brain Res. 240, 119-133. doi: 10.1016/j.bbr.2012.11.028
153. Young, J. W., Meves, J. M., Tarantino, I. S., Caldwell, S., and Geyer, M. A. (2011). Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 10, 720-733. doi: 10.1111/j.1601-183X.2011.00711.x
154. Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., and Geyer, M. A. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150-202. doi: 10.1016/j.pharmthera.2009.02.004
155. Young, J. W., Zhou, X., and Geyer, M. A. (2010). Animal models of schizophrenia. Curr. Top. Behav. Neurosci. 4, 391-433. doi: 10.1007/7854_2010_62
156. Zhang, J., Chen, X., Yu, L., Zhen, X., and Zhang, A. (2008). Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D(1) receptor activities. Bioorg. Med. Chem. 16, 9425-9431. doi: 10.1016/j.bmc.2008.09.049